Saniona ion channel research collaboration with Boehringer Ingelheim advances to next stage
March 21 2022 - 2:00AM
Saniona ion channel research collaboration with Boehringer
Ingelheim advances to next stage
PRESS RELEASE
March 21,
2022
Saniona (OMX: SANION), a clinical stage
biopharmaceutical company focused on rare diseases, today
announced that its
ongoing ion channel research collaboration
with Boehringer Ingelheim has
advanced to the next
stage.
“After successful completion of target validation, library
screening and generation of selective hits, Saniona and Boehringer
Ingelheim have agreed to progress our ongoing ion channel research
collaboration into the ‘hit-to-lead’ stage,” said Jørgen Drejer,
Founder and Chief Scientific Officer of Saniona. “We look forward
to continuing our partnership with Boehringer Ingelheim scientists
as we work together to identify novel ion channel modulators to
treat cognitive deficits in schizophrenia.”
Saniona and Boehringer Ingelheim entered into the ongoing
research collaboration in 2020. The collaboration is focused on a
novel, undisclosed CNS ion channel target for schizophrenia.
Saniona receives ongoing research funding and may receive up to
€76.5 million in milestone payments as well as royalties on
worldwide net sales.
For more information, please contact Trista
Morrison, Chief Corporate Affairs Officer, Saniona. Office: + 1
(781) 810-9227. Email: trista.morrison@saniona.com
The information was submitted for publication, through the
agency of the contact person set out above, at 8:00 CET on 21 March
2022.
About Saniona Saniona is a clinical-stage
biopharmaceutical company focused on discovering, developing and
commercializing innovative therapies for patients suffering from
rare diseases for which there are a lack of available treatment
options. The company’s lead product candidate, Tesomet™, is in
mid-stage clinical trials for hypothalamic obesity and Prader-Willi
syndrome, serious rare disorders characterized by severe weight
gain, disturbances of metabolic functions and uncontrollable
hunger. Saniona has developed a proprietary ion channel drug
discovery engine anchored by IONBASE™, a database of more than
130,000 compounds, of which more than 20,000 are Saniona’s
proprietary ion channel modulators. Through its ion channel
expertise, Saniona is advancing two wholly-owned ion channel
modulators, SAN711 and SAN903. SAN711 is in a Phase 1 clinical
trial and may be applicable in the treatment of rare neuropathic
disorders, and SAN903 is in preclinical development for rare
inflammatory, fibrotic and hematological disorders. Led by an
experienced scientific and operational team, Saniona has an
established research organization in the Copenhagen area, Denmark,
and a corporate office in the Boston, Massachusetts area, U.S. The
company’s shares are listed on Nasdaq Stockholm Small Cap (OMX:
SANION). Read more at http://www.saniona.com.
- BI update Press Release 03.21.22
Saniona Ab (LSE:0RQJ)
Historical Stock Chart
From Feb 2025 to Mar 2025
Saniona Ab (LSE:0RQJ)
Historical Stock Chart
From Mar 2024 to Mar 2025
